Telomir Pharmaceuticals, Inc. announced that its lead candidate, Telomir-1, demonstrated a clear, dose-dependent reduction in viability of HL60 human leukemia cells in an in-vitro assay. The company said this finding marks an extension of Telomir-1’s activity into blood-cancer models, adding to previously reported results in solid tumours. The study involved treatment of leukemia cells with Telomir-1, which produced measurable decreases in viable cells and supports the drug’s mechanism of action involving intracellular iron modulation and epigenetic regulation in aggressive cancer types.
According to the company, leukemia cells are particularly vulnerable to disruptions in iron-dependent metabolic and epigenetic pathways, which Telomir-1 is designed to target. In prior research, the company reported that Telomir-1 could reduce intracellular ferrous iron at low micromolar concentrations, reverse hypermethylation of several tumour-suppressor genes, and inhibit multiple histone-demethylase enzyme families. These mechanistic insights form the basis of Telomir-1’s development in oncology, including the newly targeted leukemia indication.
While the new data are promising, Telomir emphasizes that they are strictly laboratory-based and that Telomir-1 remains at the pre-clinical development stage. The company did not report any animal-model or human clinical data in leukemia. The announcement serves as a scientific update, and future work will need to validate efficacy, safety and translational relevance in vivo before the compound can advance toward IND-enabling studies.
